Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.75 |
| ▸ | RAB9A | P51151 | 8/20 | 0.75 |
| ▸ | MEN1 | O00255 | 8/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.66 |
| ▸ | RELA | Q04206 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | CASP2 | P42575 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443652 | 0.84 | MAPK1 (0.67) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL8868420 | 0.83 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL8868426 | 0.83 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL29684837 | 0.82 | RAB9A (0.71) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL12495837 | 0.82 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL22804218 | 0.82 | NPC1 (0.83) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL8771200 | 0.82 | NPC1 (0.89) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL19392293 | 0.82 | NPC1 (0.89) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL16298403 | 0.81 | NPC1 (0.80) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL2063276 | 0.80 | NPC1 (0.86) | NPC1RAB9AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4738766-A2 | DATA TRANSMISSION CONTROL METHOD AND SYSTEM, AND FIRST END, DEVICE AND READABLE STORAGE MEDIUM | Huang, Jianfang (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20250069572-A1 | SCALE SHIFTING AND VOLUME ADJUSTMENT METHODS, APPARATUS, AND DEVICE | RINGWAY TECH (JIANGSU) CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| US-20240029765-A1 | Methods for Programming and Accessing Resistive Change Elements Using Neutral Voltage Conditions | NANTERO, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11817171-B2 | Devices for providing neutral voltage conditions for resistive change elements in resistive change element arrays | NANTERO, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-110291148-B | Rubber composition for conveyor belt, method for producing rubber composition for conveyor belt, and belt conveyor | 横滨橡胶株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-20220028435-A1 | Devices for Providing Neutral Voltage Conditions for Resistive Change Elements in Resistive Change Element Arrays | NANTERO, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8093291-B2 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8063057-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2386547-A1 | Multicyclic amino acid derivatives and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-8039086-B2 | Bonding material, process for producing the same, and honeycomb structure made with the same | NGK INSULATORS, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011100285-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011056916-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TERSERA THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-7875622-B2 | administering to a patient A therapeutically effective amounts of an endothelin receptor antagonist e.g. ambrisentan, bosentan etc. and (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid to treat pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TPH1, TPH2, PTGIS | NPC1 4278/4885RAB9A 3956/4885MEN1 2873/4885 |
| US-20110263601-A1 | METHODS OF TREATING ULCERATIVE COLITIS | TPH2, TPH1, HNMT | NPC1 4113/4885RAB9A 4199/4885MEN1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.